Arcus Biosciences 2Q23 Earnings Presentation August 2023

Arcus Biosciences presents its 2Q23 financial results and corporate updates on its late-stage oncology pipeline. The company showcases its productive R&D engine delivering 1-2 new development candidates annually, with multiple Phase 3 studies in lung and gastric cancers. Key partnerships with Gilead, Taiho, and AstraZeneca support commercialization of precision combination therapies targeting immuno-oncology and cell-intrinsic pathways.